Background:Irritable bowel syndrome(IBS)is a chronic functional bowel disorder characterized by abdominal pain and altered bowel function.The TongXieYaoFang(TXYF)is a Chinese herbal formula with a long history for the...Background:Irritable bowel syndrome(IBS)is a chronic functional bowel disorder characterized by abdominal pain and altered bowel function.The TongXieYaoFang(TXYF)is a Chinese herbal formula with a long history for the management of chronic diarrhea accompanied by abdominal pain,and it is always used to relieve symptoms of IBS.Although there are some studies were published,there is no consensus on its effects.Moreover,new relevant study was published recently.Therefore,a systematic review and meta-analysis is needed to assess the safety and eff ectiveness of the Chinese herbal medicine TongXieYaoFang for IBS.Methods and analysis:PubMed,EMBASE,the Cochrane library,CNKI,WanFang,VIP and CBM databases will be searched without search date and language restrictions.We will include randomized controlled trial(RCT)comparing TXYF with another therapy method for IBS.The quality of included studies will be independently assessed using Risk of bias tool in the Cochrane Handbook 5.1.0,and be categorized as being at low,unclear or high risk of bias.The primary outcome is the disappearance and significant improvement in global symptoms,and the secondary outcomes including visual analog scale(VAS)score,adverse event,rehospitalization rate and the quality of life.The Meta-analysis will be performed using the Cochrane Collection’s tool RevMan 5.3 software.Results:This study is ongoing and will be submitted to a peerreviewed journal for publication.Conclusion:This study will provide a confirmed evidence on the safety and eff ectiveness of TXYF for IBS.Ethics and dissemination:Ethical approval and patient consent are not required because of the study is a systematic review and meta-analysis based on literatures.The results of this study will be submitted to a peer-reviewed journal for publication.展开更多
OBJECTIVE: To explore the underlying mechanism of action of Tongxieyaofang decoction in rats with visceral hypersensitivity using proteomics technology.METHODS: Twenty-four female Sprague-Dawley rats were randomly div...OBJECTIVE: To explore the underlying mechanism of action of Tongxieyaofang decoction in rats with visceral hypersensitivity using proteomics technology.METHODS: Twenty-four female Sprague-Dawley rats were randomly divided into three groups: control group, irritable bowel syndrome(IBS) group and Tongxieyaofang treatment group. An IBS model, characterized as visceral hypersensitivity, was established using the odour of mothballs as conditional stimulation and colorectal distension combined with classic physical restraint as non-conditional stimulation. Rats were intragastrically treated with Tongxieyaofang(2 or 4 m L · kg^(-1)· d^(-1))for 4 weeks. On the 45 th day, the rats were dissected and the colonic mucosal proteins were extracted. Differential protein spots were screened by fluorescent two-dimensional differential gel electrophoresis(2 D-DIGE), and identified by matrix-assisted laser desorption/ionisation time of flight mass spectrometry(MALDI-TOF-MS). Western blotting experiments were performed to verify the changes observed in 2 D-DIGE and MALDI-TOF-MS.RESULTS: It was found that the visceral sensitivity of rats in the Tongxieyaofang treatment group(4 m L/kg) was lower than that in the IBS group(P <0.01). Sixty-one protein spots were differentially expressed between the IBS group and the Tongxieyaofang treatment group. Of these, 23 spots were upregulated in the Tongxieyaofang treatment group, while 38 spots were downregulated. Three specific proteins were successfully identified from the five protein spots with the most obvious changes. The two upregulated proteins were transgelin(TAGLN) and acetaldehyde dehydrogenase 2(Aldh2) and the downregulated protein was cytokeratin 8(CK8).CONCLUSION: Tongxieyaofang can dose-dependently ameliorate visceral hypersensitivity in rats and the mechanism of action may involve the upregulation of TAGLN and Aldh2 and the downregulation of CK8.展开更多
文摘Background:Irritable bowel syndrome(IBS)is a chronic functional bowel disorder characterized by abdominal pain and altered bowel function.The TongXieYaoFang(TXYF)is a Chinese herbal formula with a long history for the management of chronic diarrhea accompanied by abdominal pain,and it is always used to relieve symptoms of IBS.Although there are some studies were published,there is no consensus on its effects.Moreover,new relevant study was published recently.Therefore,a systematic review and meta-analysis is needed to assess the safety and eff ectiveness of the Chinese herbal medicine TongXieYaoFang for IBS.Methods and analysis:PubMed,EMBASE,the Cochrane library,CNKI,WanFang,VIP and CBM databases will be searched without search date and language restrictions.We will include randomized controlled trial(RCT)comparing TXYF with another therapy method for IBS.The quality of included studies will be independently assessed using Risk of bias tool in the Cochrane Handbook 5.1.0,and be categorized as being at low,unclear or high risk of bias.The primary outcome is the disappearance and significant improvement in global symptoms,and the secondary outcomes including visual analog scale(VAS)score,adverse event,rehospitalization rate and the quality of life.The Meta-analysis will be performed using the Cochrane Collection’s tool RevMan 5.3 software.Results:This study is ongoing and will be submitted to a peerreviewed journal for publication.Conclusion:This study will provide a confirmed evidence on the safety and eff ectiveness of TXYF for IBS.Ethics and dissemination:Ethical approval and patient consent are not required because of the study is a systematic review and meta-analysis based on literatures.The results of this study will be submitted to a peer-reviewed journal for publication.
文摘OBJECTIVE: To explore the underlying mechanism of action of Tongxieyaofang decoction in rats with visceral hypersensitivity using proteomics technology.METHODS: Twenty-four female Sprague-Dawley rats were randomly divided into three groups: control group, irritable bowel syndrome(IBS) group and Tongxieyaofang treatment group. An IBS model, characterized as visceral hypersensitivity, was established using the odour of mothballs as conditional stimulation and colorectal distension combined with classic physical restraint as non-conditional stimulation. Rats were intragastrically treated with Tongxieyaofang(2 or 4 m L · kg^(-1)· d^(-1))for 4 weeks. On the 45 th day, the rats were dissected and the colonic mucosal proteins were extracted. Differential protein spots were screened by fluorescent two-dimensional differential gel electrophoresis(2 D-DIGE), and identified by matrix-assisted laser desorption/ionisation time of flight mass spectrometry(MALDI-TOF-MS). Western blotting experiments were performed to verify the changes observed in 2 D-DIGE and MALDI-TOF-MS.RESULTS: It was found that the visceral sensitivity of rats in the Tongxieyaofang treatment group(4 m L/kg) was lower than that in the IBS group(P <0.01). Sixty-one protein spots were differentially expressed between the IBS group and the Tongxieyaofang treatment group. Of these, 23 spots were upregulated in the Tongxieyaofang treatment group, while 38 spots were downregulated. Three specific proteins were successfully identified from the five protein spots with the most obvious changes. The two upregulated proteins were transgelin(TAGLN) and acetaldehyde dehydrogenase 2(Aldh2) and the downregulated protein was cytokeratin 8(CK8).CONCLUSION: Tongxieyaofang can dose-dependently ameliorate visceral hypersensitivity in rats and the mechanism of action may involve the upregulation of TAGLN and Aldh2 and the downregulation of CK8.
